• Mashup Score: 9

    The Assistant Secretary for Preparedness and Response (ASPR) announced a pause in sotrovimab distribution in regions where BA.2 is the dominant COVID-19 variant, citing evidence that the monoclonal antibody therapy would not effectively neutralize the BA.2 Omicron variant.

    Tweet Tweets with this article
    • #Breaking: There will be a pause in #sotrovimab distribution in regions where #BA2 is the dominant COVID-19 variant. Evidence suggests the monoclonal antibody therapy will not effectively neutralize the BA.2 Omicron subvariant. https://t.co/t8Fpa2kRx2

  • Mashup Score: 0

    By now, you’ve no doubt heard that scientists are tracking a rise in COVID-19 cases in Europe caused by BA.2, a sub-variant of the omicron variant of COVID-19. As of mid-March, experts say BA.2 makes up about a third of the cases of COVID-19 in the United States. But what does that mean and is it a cause for concern about another surge? Atrium Health Infectious Diseases physician, Dr. Anupama…

    Tweet Tweets with this article
    • As scientists track a rise in #COVID19 cases in Europe caused by #BA2, a sub-variant of omicron, @AtriumHealth experts are breaking down what it means for you and your family. https://t.co/NG8YcZE9L2 #staysafe #getvaccinated

  • Mashup Score: 2

    The monoclonal antibody sotrovimab is no longer authorized by the FDA to treat COVID-19 in certain U.S. regions with high frequency of the omicron BA.2 subvariant. In a statement released March 25, the FDA said it was limiting the use of sotrovimab (Xevudy, GlaxoSmithKline) in some U.S. regions, mostly along the east coast, following data showing that the authorized dose of the monoclonal

    Tweet Tweets with this article
    • The monoclonal antibody #sotrovimab is no longer authorized by the #FDA to treat #COVID19 in certain U.S. regions with high frequency of the #omicron #BA2 subvariant https://t.co/nslRLxp3ji